| 17.79 0.51 (2.95%) | 06-18 09:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.92  |
1-year : | 22.42 |
| Resists | First : | 17.91 |
Second : | 19.2 |
| Pivot price | 18.12 |
|||
| Supports | First : | 15.84 |
Second : | 13.17 |
| MAs | MA(5) : | 18.08 |
MA(20) : | 18.24  |
| MA(100) : | 19.14 |
MA(250) : | 16.95 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 42.6 |
D(3) : | 55.7 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 24.32 | Low : | 10.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CBLL ] has closed above bottom band by 7.3%. Bollinger Bands are 39.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.14 - 18.26 | 18.26 - 18.36 |
| Low: | 16.84 - 16.96 | 16.96 - 17.05 |
| Close: | 17.11 - 17.3 | 17.3 - 17.45 |
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Wed, 17 Jun 2026
CeriBell Inc (CBLL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 15 Jun 2026
Insider Sell Alert: Joseph Taylor Sells 5,500 Shares of CeriBell Inc (CBLL) - GuruFocus
Mon, 08 Jun 2026
AI EEG tool links ICU seizure burden to death and disability risk - Stock Titan
Wed, 03 Jun 2026
Ceribell Announces Director Elections at 2026 Annual Meeting - The Globe and Mail
Mon, 01 Jun 2026
InvestingPro’s Fair Value warned of CeriBell crash 17 months ago By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 12.8 (%) |
| Held by Institutions | 86.7 (%) |
| Shares Short | 1,920 (K) |
| Shares Short P.Month | 1,880 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.72 |
| Profit Margin | -63.5 % |
| Operating Margin | -78.4 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | -37.6 % |
| Qtrly Rev. Growth | 29.2 % |
| Gross Profit (p.s.) | 2.19 |
| Sales Per Share | 2.5 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -10.67 |
| PEG Ratio | 0 |
| Price to Book value | 4.64 |
| Price to Sales | 6.89 |
| Price to Cash Flow | -13.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|